- Ecolab Inc ECL reported third-quarter FY22 sales growth of 10% year-on-year to $3.669 billion, marginally beating the consensus of $3.66 billion.
- Sales from Global Industrial rose 16%, Global Institutional & Specialty climbed 12%, Global Healthcare & Life Sciences grew 34% Y/Y in fixed currency.
- Adjusted EPS of $1.30 missed the analyst consensus of $1.31.
- Selling, general and administrative expenses rose 5% Y/Y. The operating margin was 13.2%, and operating income for the quarter rose 4% to $483 million.
- The company held $112.9 million in cash and equivalents as of September 30, 2022.
- Ecolab said it is preparing for a more challenging macroeconomic environment, especially in Europe, with high delivered product costs and unfavorable currency translation impacts that are expected to persist well into 2023.
- ECL expects to deliver a continued strong acceleration in Q4 operating income growth. It sees Q4 adjusted EPS approaching last year's $1.28, below the consensus of $1.49.
- Price Action: ECL shares are trading lower by 8.79% at $143.35 on the last check Tuesday.
- Photo Via Wikimedia Commons
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.